Overview

Bococizumab HIV Evaluation (B-HIVE) Study

Status:
Terminated

Trial end date:
2017-11-01

Target enrollment:

Participant gender:

Summary

B-HIVE is a Phase 3, double blind, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of bococizumab 150 mg subcutaneously every 2 weeks to bococizumab placebo subcutaneously every 2 weeks for LDL-C lowering in HIV-infected subjects.

Phase:

Phase 3

Details

Lead Sponsor:

University of California, San Francisco

Collaborators:

Pfizer
San Francisco General Hospital

Treatments:

Bococizumab